Assembly Biosciences exec sells more than $15,000 in stock Author:

Assembly Biosciences, Inc. (NASDAQ: ) reported a recent transaction involving its chief manufacturing officer, Nicole S. White, who sold stock in the company. The sale took place on April 30, 2024, and involved 1,255 shares at an average price of $12.7068, for a total value of over $15,947.

The transaction was part of a “clawback,” a common practice for executives to satisfy their withholding tax obligations related to the vesting of stock awards. The shares were sold to satisfy withholding tax obligations as part of the vesting and settlement of restricted stock units, according to a footnote in the filing. This process is mandated by management rules adopted by the Compensation Committee of Assembly Biosciences' Board of Directors and does not represent a discretionary sale by White.

Additionally, the shares were sold at prices ranging from $12.3851 to $12.8847. White undertakes to provide complete information upon request regarding the number of shares sold at each individual price.

In addition to the sale, White also acquired 3,333 shares of common stock on April 29, 2024, as part of a performance-based restricted stock unit award dated August 1, 2022. The shares were granted following the achievement of a performance-based vesting Status. These shares are purchased free of charge because they are part of a predetermined compensation plan.

Upon completion of these transactions, Nicole S. White's ownership in Assembly Biosciences will reach 13,025 common shares. Stock sales and acquisitions by company executives are often disclosed to the public through filings with the Securities and Exchange Commission, providing transparency into the financial activities of company insiders.

3rd party advertising. Not an offer or recommendation by disclosures here or
Remove ads

Investment Professional Insights

Assembly Biosciences, Inc. (NASDAQ: ASMB ) is seeing some noteworthy financial metrics that are worth considering given the recent insider trading. With a market capitalization of approximately $72.76 million and a price-to-book ratio of 1.79 for the trailing twelve months ended Q4 2023, the company has some valuation prospects. Despite a challenging profitability situation, with no dividends paid to shareholders over the last twelve months and a lack of profitability, there are positive signs for the company's financial structure.

one of the Investment Professional Tips Point out that Assembly Biosciences holds more cash than debt on its balance sheet, which could provide it with some financial flexibility in its operations. Additionally, analysts expect sales growth this year, which could indicate the potential for revenue growth. However, it's worth noting that analysts don't expect the company to make a profit this year.

From the data provided, the gross profit margin for the trailing twelve months to Q4 2023 was as high as 70.46%, indicating that the company has effectively maintained a high gross profit margin level relative to revenue, which stood at $7.16 million. period.

There is also additional content for readers interested in a deeper understanding of the company's financial health and future prospects. Investment Professional Tips The information available includes insights into the company's valuation, which implies strong free cash flow yields and liquid assets in excess of short-term debt.To access these tips and more, use the coupon code PRONEWS24 Get an additional 10% discount on annual or two-year Pro and Pro+ subscriptions at InvestingPro. InvestingPro has listed a total of 7 tips that can provide further guidance to investors and stakeholders interested in Assembly Biosciences.

3rd party advertising. Not an offer or recommendation by disclosures here or
Remove ads

This article was generated with the support of artificial intelligence and reviewed by an editor. For more information, please see our terms and conditions.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *